Mark Leiser

A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of OS, according to the agents’ manufacturerTiragolumab (Genentech/Roche) is an immunotherapy designed to bind to TIGIT, a protein receptor on immune cells. Atezolizumab (Tecentriq, Genentech/Roche) is an anti-PD-L1 therapy.

SAN DIEGO — Increased fiber intake after allogeneic hematopoietic stem cell transplantation appeared linked to improved outcomes, according to study results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — A higher ferritin threshold than that used by WHO and CDC is cost-effective for identifying and treating women with iron deficiency, according to study results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — A bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage

SAN DIEGO — Etavopivat reduced the annualized vaso-occlusive crises rate vs. placebo for people with sickle cell disease, according to study data presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Epcoritamab exhibited encouraging efficacy among heavily pretreated patients with advanced chronic lymphocytic leukemia, according to study results presented at ASH Annual Meeting and Exposition.

Key takeaways: Lower neighborhood education level appeared linked to reduced likelihood of HSCT.

SAN ANTONIO — The addition of pyrotinib to first-line trastuzumab and docetaxel improved PFS among patients with HER2-positive metastatic breast

SAN ANTONIO — The addition of palbociclib to standard care extended median PFS for patients with hormone receptor-positive, HER2-positive metastatic

SAN ANTONIO — Elevated BMI increased risk for breast cancer mortality and distant recurrence among women with early-stage disease, according to findings presented at San Antonio Breast Cancer Symposium.